Senior Vice President, Clinical Development, Virology Therapeutic Area Head at Gilead Sciences.
Further Data Finds Lenacapavir to Be Safe and Tolerable for PrEP Use
Published: October 15th 2024 | Updated: October 15th 2024The Gilead capsid inhibitor has been shown to have less adverse events compared to another PrEP, and the company plans to begin regulatory filings for approval before the end of this year.
Read More